Q1 2027 Sai Life Sciences Ltd Earnings Call Transcript
Key Points
- Revenue grew 12% year-over-year, with CRO segment up 26%, driven by strong demand and strategic partnerships.
- Successfully converted a pilot collaboration with a large pharma company into a long-term, high-volume discovery chemistry partnership.
- Added six late-phase molecules to the pipeline over the last 15 months, with five from large pharma FTE relationships, enhancing future commercial manufacturing potential.
- Expanding into new modalities like peptides and ADC, with a dedicated peptide development lab and XPP Center of Excellence, positioning for future growth.
- Maintained strong customer loyalty with over 90% of revenue from returning customers, and secured EcoVadis Platinum Rating for sustainability.
- CDMO revenue growth was modest at 6% year-over-year, reflecting lumpiness in the business.
- Heavy capital expenditure guidance of 1,100-1,300 crore for FY27, with significant investments in new capabilities like peptides and formulation, which may pressure near-term returns.
- Formulation capabilities are still six months away from operational readiness, with no immediate revenue contribution.
- Peptide commercial manufacturing facility is not expected to be operational until 2028, delaying potential revenue from this high-growth area.
- The company faces execution risks in transitioning large pharma customers to integrated models, with only two expected to convert this year.
Ladies and gentlemen, good day and welcome to the Sai Life Sciences Limited Q1 FY27 earnings conference call. ( Operators Instructions ) Please note that this conference is being recorded. I now hand the conference over to Mr. Diwakara Pingle from ENY Investor Relations. Thank you, and over to you, sir.
Thank you so much, Taga. Good evening to all the participants on this call. Warmly welcome you to the Q1 FY '27 earnings call of 5 Licenses Limited.
Before we proceed on the call, let me remind you that the discussion may contain forward-looking statements that may known unknown risks, uncertainties and other factors. It must be viewed in conjunction with our business risks that could cause future results performance or achievement to differ significantly from what is expressed or implied by such forward-looking statements.
Please note that we have made the results and the same are available on our website too. In case you have not received the same, you can write to my team at EY and we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
